Over 35,000 Americans provided comments on the Drug Enforcement Administration’s (DEA) proposed rule, “Telemedicine Prescribing of Controlled Substances When the Practitioner and the Patient Have Not Had a Prior In-Person Medical Evaluation.”

In comment letters responding to the DEA’s proposed rule, hundreds of key stakeholders highlighted the need for a special registration for telemedicine and the dangerous impact on patient access the proposed rule has on millions of patients.

Read a snapshot of the comments below or here.

Loader Loading...
EAD Logo Taking too long?

Reload Reload document
| Open Open in new tab

Download [1.32 MB]